Cargando…
Epidemiological features of COVID-19 in Iran
BACKGROUND: The first confirmed case of COVID-19 in Iran was reported in February 2019. The current study aimed to investigate the epidemiological aspects of COVID-19 disease in Isfahan province and evaluate the chances of infection and death in the population. MATERIALS AND METHODS: In this cross-s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639716/ https://www.ncbi.nlm.nih.gov/pubmed/36353336 http://dx.doi.org/10.4103/jrms.jrms_1387_20 |
_version_ | 1784825697354645504 |
---|---|
author | Tavakolifard, Negah Moeini, Mina Haddadpoor, Asefeh Amini, Zahra Heidari, Kamal Rezaie, Mostafa |
author_facet | Tavakolifard, Negah Moeini, Mina Haddadpoor, Asefeh Amini, Zahra Heidari, Kamal Rezaie, Mostafa |
author_sort | Tavakolifard, Negah |
collection | PubMed |
description | BACKGROUND: The first confirmed case of COVID-19 in Iran was reported in February 2019. The current study aimed to investigate the epidemiological aspects of COVID-19 disease in Isfahan province and evaluate the chances of infection and death in the population. MATERIALS AND METHODS: In this cross-sectional study, 21,203 confirmed cases of COVID-19, based on the polymerase chain reaction test, referred to outpatient facilities from February 2019 to July 2020 in Isfahan province are studied. Disease incidence, mortality, and case fatality rate, as well as odds ratio (OR) of infection and death, were calculated and analyzed using SPSS version 20. RESULTS: The highest incidence of the disease was within the age group of 30–39 years 4911 (23.9%) and males 11,561 (54.5%). Mortality in people over 80 years (207 [32.9%]), men (370 cases [58.7%]), diabetics (182 cases [28.9%]), and people with cardiovascular disease (165 people [26.2%]) was more. In multivariate analysis, patients with a cancer diagnosis had the highest OR of death (OR = 4.03 confidence interval [CI]: 2.56–6.35) (P < 0.001), followed by those with immune deficiency disease (OR = 2.46 CI: 1.07–5.63) (P = 0.03). As the number of comorbidities increased, the risk of death increased in the total population, so that in patients with more than 4 underlying diseases, compared to the group without disease, the chance of death increased 6.33 times. CONCLUSION: This study showed that people with cancer and chronic respiratory disease had a higher chance of COVID-19 infection. People over the age of 60, people with cancer, and immunodeficiency also had a higher chance of COVID-19 mortalityW. |
format | Online Article Text |
id | pubmed-9639716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-96397162022-11-08 Epidemiological features of COVID-19 in Iran Tavakolifard, Negah Moeini, Mina Haddadpoor, Asefeh Amini, Zahra Heidari, Kamal Rezaie, Mostafa J Res Med Sci Original Article BACKGROUND: The first confirmed case of COVID-19 in Iran was reported in February 2019. The current study aimed to investigate the epidemiological aspects of COVID-19 disease in Isfahan province and evaluate the chances of infection and death in the population. MATERIALS AND METHODS: In this cross-sectional study, 21,203 confirmed cases of COVID-19, based on the polymerase chain reaction test, referred to outpatient facilities from February 2019 to July 2020 in Isfahan province are studied. Disease incidence, mortality, and case fatality rate, as well as odds ratio (OR) of infection and death, were calculated and analyzed using SPSS version 20. RESULTS: The highest incidence of the disease was within the age group of 30–39 years 4911 (23.9%) and males 11,561 (54.5%). Mortality in people over 80 years (207 [32.9%]), men (370 cases [58.7%]), diabetics (182 cases [28.9%]), and people with cardiovascular disease (165 people [26.2%]) was more. In multivariate analysis, patients with a cancer diagnosis had the highest OR of death (OR = 4.03 confidence interval [CI]: 2.56–6.35) (P < 0.001), followed by those with immune deficiency disease (OR = 2.46 CI: 1.07–5.63) (P = 0.03). As the number of comorbidities increased, the risk of death increased in the total population, so that in patients with more than 4 underlying diseases, compared to the group without disease, the chance of death increased 6.33 times. CONCLUSION: This study showed that people with cancer and chronic respiratory disease had a higher chance of COVID-19 infection. People over the age of 60, people with cancer, and immunodeficiency also had a higher chance of COVID-19 mortalityW. Wolters Kluwer - Medknow 2022-09-27 /pmc/articles/PMC9639716/ /pubmed/36353336 http://dx.doi.org/10.4103/jrms.jrms_1387_20 Text en Copyright: © 2022 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Tavakolifard, Negah Moeini, Mina Haddadpoor, Asefeh Amini, Zahra Heidari, Kamal Rezaie, Mostafa Epidemiological features of COVID-19 in Iran |
title | Epidemiological features of COVID-19 in Iran |
title_full | Epidemiological features of COVID-19 in Iran |
title_fullStr | Epidemiological features of COVID-19 in Iran |
title_full_unstemmed | Epidemiological features of COVID-19 in Iran |
title_short | Epidemiological features of COVID-19 in Iran |
title_sort | epidemiological features of covid-19 in iran |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639716/ https://www.ncbi.nlm.nih.gov/pubmed/36353336 http://dx.doi.org/10.4103/jrms.jrms_1387_20 |
work_keys_str_mv | AT tavakolifardnegah epidemiologicalfeaturesofcovid19iniran AT moeinimina epidemiologicalfeaturesofcovid19iniran AT haddadpoorasefeh epidemiologicalfeaturesofcovid19iniran AT aminizahra epidemiologicalfeaturesofcovid19iniran AT heidarikamal epidemiologicalfeaturesofcovid19iniran AT rezaiemostafa epidemiologicalfeaturesofcovid19iniran |